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Abstract
Background: Interferon beta (IFNb) and glatiramer acetate (GA) are administered by subcutaneous (SC) or
intramuscular (IM) injection. Patients with multiple sclerosis (MS) often report injection-site reactions (ISRs) as a
reason for noncompliance or switching therapies. The aim of this study was to compare the proportion of patients
on different formulations of IFNb or GA who experienced ISRs and who switched or discontinued therapy because
of ISRs.
Methods: The Swiss MS Skin Project was an observational multicenter study. Patients with MS or clinically isolated
syndrome who were on the same therapy for at least 2 years were enrolled. A skin examination was conducted at
the first study visit and 1 year later.
Results: The 412 patients enrolled were on 1 of 4 disease-modifying therapies for at least 2 years: IM IFNb-1a (n =
82), SC IFNb-1b (n = 123), SC IFNb-1a (n = 184), or SC GA (n = 23). At first evaluation, ISRs were reported by fewer
patients on IM IFNb-1a (13.4%) than on SC IFNb-1b (57.7%; P < 0.0001), SC IFNb-1a (67.9%; P < 0.0001), or SC GA
(30.4%; P = not significant [NS]). No patient on IM IFNb-1a missed a dose in the previous 4 weeks because of ISRs,
compared with 5.7% of patients on SC IFNb-1b (P = 0.044), 7.1% of patients on SC IFNb-1a (P = 0.011), and 4.3% of
patients on SC GA (P = NS). Primary reasons for discontinuing or switching therapy were ISRs or lack of efficacy.
Similar patterns were observed at 1 year.
Conclusions: Patients on IM IFNb-1a had fewer ISRs and were less likely to switch therapies than patients on other
therapies. This study may have implications in selecting initial therapy or, for patients considering switching or
discontinuing therapy because of ISRs, selecting an alternative option.
Background
Interferon beta (IFNb) and glatiramer acetate (GA) are
first-line therapies for the long-term treatment of multi-
ple sclerosis (MS) and are generally believed to have
comparable efficacy. IFNb-1b, IFNb-1a, and GA are
administered by either intramuscular (IM) or subcuta-
neous (SC) injection, the frequency of which varies from
daily to weekly depending on the product. The injection
of these therapies can be associated with severe adverse
skin reactions, such as necrosis and lipoatrophy [1-4],
which patients may experience after years of treatment.
The frequency of injections and injection-site reactions
(ISRs) can be burdensome for patients and these reac-
tions are, among other side effects, a major reason for
poor adherence with these medications over the long
term [5-7]. O’Rourke and Hutchinson reported that
patients stopped IFNb therapy because of side effects
after a median of 13 months [6]. Since poor medication
adherence or discontinuation can lead to treatment fail-
ure and ultimately poorer long-term prognosis, it is cri-
tical that patients persist with treatment to achieve
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observational study was to compare the proportion of
patients on different formulations of IFNb or GA who
experienced ISRs and who switched or discontinued
therapy because of ISRs.
Methods
Study design and participants
The Swiss MS Skin Project was an observational study
supported by Biogen Idec Inc. and conducted at 31 sites
in Switzerland. This was a noninterventional and obser-
vational study; therefore, approval from an ethics com-
mittee or health authority was not required. Written
informed consent was obtained from all patients before
any study-related procedures were performed.
Men or women between the ages of 18 and 55 years
with relapsing MS or clinically isolated syndrome (CIS)
were enrolled. Information on demographic characteris-
tics, current MS therapy and duration, and concomitant
disease and medication were collected at study entry.
Patients were not naive to therapy and were required
to be on 1 of 4 disease-modifying therapies (DMTs) for
at least 2 years prior to enrollment: IM IFNb-1a (Avo-
nex
®), SC IFNb-1b (Betaseron
®/Betaferon
®), SC IFNb-
1a (Rebif
®), or SC GA (Copaxone
®). Rebif New Formu-
lation was not approved in Switzerland at the time of
this study. A thorough skin exam was performed on
patients who met all inclusion criteria. During this first
evaluation, all observed ISRs were recorded, with addi-
tional data (number of occurrences and severity) col-
lected for cases of necrosis and lipoatrophy. Patients
were asked whether an injection was omitted in the pre-
vious 4 weeks because of skin reactions, and, if so, the
number of injections missed was recorded. Changes in
therapy, including treatment discontinuation, or a
patient’s desire to change or discontinue treatment and
the reason were also noted. A follow-up skin evaluation
specific for necrosis and lipoatrophy was performed 1
year later or at early termination from the study. At the
follow-up evaluation, changes in treatment and the rea-
son for the change were recorded.
T h ep r i m a r yo u t c o m e so ft h i ss t u d yw e r et oe v a l u a t e
the proportion of patients on IFNb or GA who experi-
enced ISRs and who switched or discontinued therapy
because of ISRs.
Statistical methods
A chi-square test and a Fisher exact test were used for
comparisons between categorical variables (gender, ISR,
necrosis, lipoatrophy, injection omitted, and treatment
changed). t tests were used for comparisons between
continuous variables (age, duration of disease, and treat-
ment duration).
Results
Patient disposition and disease characteristics
Of the 501 patients screened at the start of the study,
412 met per-protocol entry criteria. Patients were cur-
rently on 1 of 4 DMTs: IM IFNb-1a (n = 82), SC IFNb-
1b (n = 123), SC IFNb-1a (n = 184), or SC GA (n = 23).
There were no significant differences in any study entry
demographic or disease characteristic across treatment
groups (Table 1). The overall mean age at enrollment
was 44.3 years (standard deviation [SD] 10.12) and the
majority of patients (69.7%) were women. The overall
mean duration of MS disease was 9.3 years (SD 6.22)
and the overall mean duration of treatment was 5.9
years (SD 2.97). Overall, 88 of 412 patients (21.4%) were
taking comedication for a concomitant disease.
The end-of-study visit was completed for 351 patients:
73 patients on IM IFNb-1a, 107 patients on SC IFNb-
1b, 156 patients on SC IFNb-1a, and 15 patients on SC
GA. The reasons for study discontinuation included lost
to follow-up (n = 37), stopped therapy (n = 8), changed
physicians (n = 6), switched therapy to natalizumab (n =
3) or mitoxantrone (n = 1), withdrew consent (n = 3),
pregnancy (n = 1), deterioration of general condition (n
= 1), and protocol violation (inclusion criteria not met,
n = 1).
First evaluation
Of the 412 patients enrolled in this study, 214 (51.9%)
reported an adverse skin reaction at the first evaluation.
ISRs were reported for fewer patients on IM IFNb-1a
( 1 1o f8 2p a t i e n t s ,1 3 . 4 % )t h a no nS CI F N b-1b (71 of
123 patients, 57.7%; P < 0.0001), SC IFNb-1a (125 of
184 patients, 67.9%; P < 0.0001), or SC GA (7 of 23
patients, 30.4%; P = not significant [NS]) (Figure 1). The
proportion of SC GA-treated patients who experienced
ISRs was also significantly lower than that for SC IFNb-
1b (P = 0.016) and SC IFNb-1a (P < 0.001). Of the 214
patients who experienced an ISR, 123 (57.5%) reported
that ISRs occurred “several times,” 74 (34.6%) reported
that they occurred “frequently,” and 8 (3.7%) reported
that they occurred “once.” Data were not available for 9
patients (4.2%).
Necrosis was reported for 18 of 412 patients (4.4%) at
the first evaluation (Table 2). No patients on IM IFNb-
1a or SC GA experienced necrosis, compared with 7 of
123 patients (5.7%) treated with SC IFNb-1b and 11 of
184 patients (6.0%) treated with SC IFNb-1a. Most of
the patients who experienced necrosis (77.8%) had 1-2
occurrences. The severity of necrosis was rated as mild
or moderate in the majority (83.3%) of these patients;
severe necrosis was reported in 1 of 7 patients (14.3%)
treated with SC IFNb-1b and 1 of 11 patients (9.1%)
treated with SC IFNb-1a. Data on the frequency and
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ing SC IFNb-1a.
At the first evaluation, lipoatrophy was reported for 34
of 412 patients (8.3%) (Table 2): 1 of 82 patients (1.2%)
treated with IM IFNb-1a, 11 of 123 patients (8.9%) trea-
ted with SC IFNb-1b, 19 of 184 patients (10.3%) treated
with SC IFNb-1a, and 3 of 23 patients (13.0%) treated
with SC GA. Lipoatrophy was experienced by signifi-
cantly fewer patients on IM IFNb- 1 at h a no nS CI F N b-
1b (P =0 . 0 2 1 ) ,o nS CI F N b-1a (P = 0.009), or on SC
GA (P = 0.032). The majority of patients who experi-
enced lipoatrophy (73.5%) had 1-3 occurrences. Five or
more occurrences of lipoatrophy were seen in 2 of 11
patients (18.2%) treated with SC IFNb- 1 ba n d6o f1 9
patients (31.6%) treated with SC IFNb-1a. The severity
of lipoatrophy was rated as mild or moderate in most
patients (91.2%); severe lipoatrophy was reported for 1
of 11 patients (9.1%) treated with SC IFNb-1b. Data on
severity were unknown for 2 patients receiving SC
IFNb-1b.
At the first evaluation, no patient on IM IFNb-1a had
missed a dose in the previous 4 weeks, compared with 7
of 123 patients (5.7%) treated with SC IFNb-1b (P =
0.044), 13 of 184 patients (7.1%) treated with SC IFNb-
1a (P = 0.011), and 1 of 23 patients (4.3%) treated with
SC GA (P = NS) (Table 2). Overall, 39 of 412 patients
(9.5%) reported wanting to switch therapies or discon-
tinue therapy at the first evaluation: 4 of 82 patients
(4.9%) treated with IM IFNb-1a, 13 of 123 patients
(10.6%) treated with SC IFNb-1b, 18 of 184 patients
(9.8%) treated with SC IFNb-1a, and 4 of 23 patients
(17.4%) treated with SC GA (Figure 2A). The primary
reasons for wanting to switch therapy were ISRs (30.8%)
and lack of efficacy (15.4%). Other reasons included
injection fatigue (7.7%), flu-like symptoms (5.1%), abnor-
mal liver function (5.1%), and cardiovascular problems
(2.6%) (Figure 3A). One patient on IM IFNb-1a switched
therapy because of ISRs or injection fatigue, compared
with 7 patients on SC IFNb-1b and 7 patients on SC
IFNb-1a. No patients on SC GA switched therapy
because of an ISR or injection fatigue.
Follow-up skin evaluation at 1 year
Adherence was comparable among the 4 DMTs at 1
year. However, a significantly higher proportion of
patients who started on IM IFNb- 1 aw e r es t i l lo nt h e
same therapy (86.6%) compared with patients on SC
IFNb-1b (79.7%), patients on SC IFNb-1a (83.2%), and
patients on SC GA (60.9%) (overall P = 0.036 [chi-
square test]) (Figure 4).
Data on necrosis were collected from 345 patients.
Ten of 345 patients (2.9%) experienced necrosis at the
injection site: 5 of 104 patients (4.8%) treated with SC
IFNb-1b and 5 of 154 patients (3.2%) treated with SC
IFNb-1a (Table 3). No patients on IM IFNb-1a or SC
GA experienced necrosis. The majority of patients who
experienced necrosis (80.0%) reported 1-2 occurrences,
and the severity was mild or moderate in most patients
(70.0%). Severe necrosis was observed in only 1 patient
treated with SC IFNb-1b. Data on the frequency and
severity of necrosis were unknown for 1 patient on SC
IFNb-1b and 1 patient on SC IFNb-1a.
Data on lipoatrophy were collected from 344 patients.
Lipoatrophy was reported in 33 of 344 patients (9.6%): 9
of 104 patients (8.7%) treated with SC IFNb-1b, 23 of
153 patients (15.0%) treated with SC IFNb-1a, and 1 of
14 patients (7.1%) treated with SC GA (Table 3). No
patient on IM IFNb-1a experienced lipoatrophy, which
Table 1 Demographic and disease characteristics of patients
a at study entry
IM IFNb-1a
(n = 82)
SC IFNb-1b
(n = 123)
SC IFNb-1a
(n = 184)
SC GA
(n = 23)
Overall
(N = 412)
Mean age, years (SD) 44.7 (10.35) 45.9 (10.23) 43.2 (9.72) 43.1 (11.25) 44.3 (10.12)
Gender, female (%) 64 (78.0) 84 (69.4) 122 (66.7) 15 (65.2) 285 (69.7)
Mean duration of MS disease, years (SD) 9.9 (7.37) 10.0 (6.29) 8.6 (5.74) 9.5 (4.92) 9.3 (6.22)
Mean duration of treatment, years (SD) 5.5 (2.56) 6.8 (3.06) 5.5 (2.93) 5.6 (3.24) 5.9 (2.97)
aThere were no statistically significant differences between the groups.
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Figure 1 Results of skin examination at the first evaluation. The
number of patients experiencing ISRs at the first evaluation was
recorded for each therapy. At the first evaluation examination,
patients had been on their current DMT for at least 2 years. *P <
0.0001 vs IM IFNb-1a; chi-square test.
†P = 0.016 vs SC IFNb-1b; P <
0.001 vs SC IFNb-1a; P = NS vs IM IFNb-1a; chi-square test.
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Page 3 of 7was significantly lower than the rate of lipoatrophy on
SC IFNb-1b (P =0 . 0 1 1 )a n dS CI F N b-1a (P < 0.0001).
At least 5 occurrences of lipoatrophy were observed in 1
of 9 patients (11.1%) treated with SC IFNb-1b and 3 of
23 patients (13.0%) treated with SC IFNb-1a. The sever-
ity of lipoatrophy was rated as mild or moderate in the
majority of patients (78.8%); severe lipoatrophy was
experienced by 1 patient treated with SC IFNb-1b and 1
patient treated with SC IFNb-1a. Frequency data were
unknown for 1 patient and severity data were unknown
for 5 patients in the SC IFNb-1a-treated group.
Data on switching or discontinuing therapy were col-
lected from 346 patients. Overall, 28 of 346 patients
(8.1%) reported wanting to switch or discontinue ther-
apy at the 1-year follow-up: 4 of 73 patients (5.5%) trea-
ted with IM IFNb-1a, 6 of 104 patients (5.8%) treated
with SC IFNb-1b, 16 of 154 patients (10.4%) treated
with SC IFNb-1a, and 2 of 15 patients (13.3%) treated
with SC GA (Figure 2B). The primary reasons for want-
ing to switch or discontinue therapy were lack of
efficacy (46.4%) and ISRs (17.9%) (Figure 3B). Other rea-
sons included injection fatigue (3.6%), flu-like symptoms
(3.6%), and abnormal liver function (3.6%). No patients
on IM IFNb-1a switched therapy because of ISRs or
injection fatigue during the 1-year study, compared with
1p a t i e n to nS CI F N b-1b, 4 patients on SC IFNb-1a,
and 1 patient on SC GA.
A logistic regression model was used to evaluate
potential relationships between stopping or switching
initial treatment at the year 1 follow-up and baseline
age, ISRs, initial treatment, gender, and disease duration.
Significant interactions were found for gender and IM
IFNb-1a versus GA. The odds of stopping or switching
initial MS treatment at the year 1 follow-up were 2.876
times higher for female patients than for male patients
(P = 0.0115). Likewise, the odds of stopping or switching
initial treatment at the year 1 follow-up were 4.877
times higher for patients on GA than for patients on IM
IFNb-1a (P = 0.0215). No significant interactions were
found for the other baseline variables.
Table 2 Skin status at first evaluation examination
IM IFNb-1a
(n = 82)
SC IFNb-1b
(n = 123)
SC IFNb-1a
(n = 184)
SC GA
(n = 23)
Overall
(N = 412)
Any ISR, n (%) 11 (13.4) 71 (57.7) 125 (67.9) 7/23 (30.4) 214 (51.9)
Necrosis, n (%) 0 (0)
a 7 (5.7) 11 (6.0) 0 (0) 18 (4.4)
Number of occurrences
1 0 1/7 (14.3) 6/11 (54.5) 0 7/18 (38.9)
2 0 4/7 (57.1) 3/11 (27.3) 0 7/18 (38.9)
3 0 1/7 (14.3) 1/11 (9.1) 0 2/18 (11.1)
4 0 1/7 (14.3) 0 0 1/18 (5.6)
Unknown 0 0 1/11 (9.1) 0 1/18 (5.6)
Severity
Mild 0 3/7 (42.9) 6/11 (54.5) 0 9/18 (50.0)
Moderate 0 3/7 (42.9) 3/11 (27.3) 0 6/18 (33.3)
Severe 0 1/7 (14.3) 1/11 (9.1) 0 2/18 (11.1)
Unknown 0 0 1/11 (9.1) 0 1/18 (5.6)
Lipoatrophy, n (%) 1 (1.2)
b 11 (8.9) 19 (10.3) 3 (13.0) 34 (8.3)
Number of occurrences
1 0 1/11 (9.1) 5/19 (26.3) 1/3 (33.3) 7/34 (20.6)
2 0 6/11 (54.5) 6/19 (31.6) 1/3 (33.3) 13/34 (38.2)
3 0 2/11 (18.2) 2/19 (10.5) 1/3 (33.3) 5/34 (14.7)
4 1/1 (100) 0 0 0 1/34 (2.9)
≥5 0 2/11 (18.2) 6/19 (31.6) 0 8/34 (23.5)
Severity
Mild 1/1 (100) 6/11 (54.5) 10/19 (52.6) 2/3 (66.7) 19.34 (55.9)
Moderate 0 2/11 (18.2) 9/19 (47.4) 1/3 (33.3) 12/34 (35.3)
Severe 0 1/11 (9.1) 0 0 1/34 (2.9)
Unknown 0 2/11 (18.2) 0 0 2/34 (5.9)
Injection omitted during last 4 weeks, n (%) 0 (0)
c 7 (5.7) 13 (7.1) 1 (4.3) 21 (5.1)
At the first evaluation examination, patients had been on their current DMT for at least 2 years.
aP = 0.028 vs SC IFNb-1b; P = 0.020 vs SC IFNb-1a.
bP = 0.021 vs SC IFNb-1b; P = 0.009 vs SC IFNb-1a; P = 0.032 vs SC GA.
cP = 0.044 vs SC IFNb-1b; P =N Sv sS CG A ;P = 0.011 vs SC IFNb-1a.
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The Swiss MS Skin Project study is the first study to
evaluate the relative frequency and severity of ISRs asso-
ciated with the 4 injectable DMTs available for patients
with MS. In our large patient population of more than
400 patients, approximately half of the patients experi-
enced ISRs at the first evaluation even though they had
been on the same therapy for at least 2 years (mean
treatment duration = 5.9 years). This finding suggests
that ISRs continue to be a concern for patients with MS
even after they have been on therapy for several years.
Indeed, ISRs and lack of efficacy were the 2 most com-
mon reasons for patients’ discontinuing treatment or
wanting to switch therapy at the first evaluation and 1-
year follow-up.
We report potentially clinically important differences
in the proportion of patients experiencing ISRs with
injectable DMTs. At the first evaluation examination,
significantly fewer patients on IM IFNb-1a than on
other IFN formulations experienced ISRs. A trend
toward lower rates of ISRs with IM IFNb-1a than with
SC GA was also reported. Missed doses in the previous
4 weeks appeared to be associated with twice the likeli-
hood of discontinuing or switching therapy for patients
on SC IFNb-1b, SC IFNb-1a, or SC GA as compared
with patients on IM IFNb-1a. ISRs were the most
common reason for switching or discontinuing therapy,
followed by lack of efficacy and injection fatigue. At the
1-year follow-up, similar patterns of ISRs and of switch-
ing or discontinuing therapy were seen. Patients on IM
IFNb-1a were significantly less likely to have necrosis or
lipoatrophy than patients on SC IFNb-1b or SC IFNb-
1a. More patients remained on IM IFNb-1a than on the
other injectable therapies. Although lack of efficacy was
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Figure 2 Patients wanting to switch or discontinue therapy at
first evaluation (A) and 1 year (B). At the first evaluation
examination, patients had been on their current DMT for at least 2
years.
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Figure 3 Reasons for switching or discontinuing therapy at the
first evaluation (A) and 1 year (B). At the first evaluation
examination, patients had been on their current DMT for at least 2
years.
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Figure 4 Patients remaining on original treatment at 1-year
follow-up. *Overall P = 0.036 (chi-square test).
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therapy, ISRs were also a common reason.
Our findings that ISRs are common and that fewer
patients treated with IM IFNb-1a than the other inject-
able therapies experience ISRs are consistent with the
findings of previous randomized, controlled studies
comparing the therapies pairwise. The EVIDENCE trial
compared IM IFNb-1a 30 μgo n c ew e e k l yt oS CI F N b-
1a 44 μg three times weekly [1]. In this study, ISRs were
the most commonly reported adverse event. ISRs were
experienced by significantly fewer patients on IM IFNb-
1a than on SC IFNb-1a (28% vs 83%, P < 0.001) [1].
Similarly, the INCOMIN open-label trial compared IM
IFNb-1a 30 μg once weekly with SC IFNb-1b 250 μg
every other day. In this study, ISRs were reported in 8%
of patients treated with IM IFNb-1a compared with 37%
of patients treated with SC IFNb-1b (P < 0.0001) [2].
These data are further supported by Milanese et al, who
showed occurrence of local reactions in 8% of IM IFNb-
1a-treated patients versus 33% of SC IFNb-1b-treated
patients [3]. Finally, BEYOND, a study of SC IFNb-1b
(250 μgo r5 0 0μg every other day) versus SC GA (20
mg daily), reported that 48%-58% of patients across
treatment groups experienced ISRs [4]. The current
study is limited by its observational nature and the low
number of patients on SC GA, which may be reflective
of low utilization of SC GA at the study sites in Switzer-
land. Given the overall mean treatment duration of 5.9
years, study patients may have received other treatments
prior to the current DMT. This possibility is important,
since a patient may have different expectations with the
first therapy than with the second or third therapy. In
addition, these results may not reflect the prevalence of
ISRs at the initiation of treatment or early in the treat-
ment regime. Nevertheless, the results are generally con-
sistent with, and may be more reflective of, clinical
practice than results from controlled clinical trials. At
both the first evaluation and 1-year follow-up examina-
tions, patients on IM IFNb-1a had fewer skin reactions
and were less likely to switch therapies than patients on
other therapies.
Maintaining patients with MS on DMTs can be chal-
lenging, particularly in the early stage of treatment,
when the benefits of therapy may not be obvious to
patients and such patients are still adjusting to their
medication. Patients with MS commonly cite the fre-
quency of injections and ISRs as reasons for missing
doses or switching or discontinuing therapies [5-8].
Patients discontinuing therap yb e c a u s eo fs i d ee f f e c t s ,
such as ISRs, often do so early during in the course of
Table 3 Skin status at one-year follow-up examination
IM IFNb-1a
(n = 73)
SC IFNb-1b
(n = 104)
SC IFNb-1a
(n = 154)
SC GA
(n = 14)
Overall
(N = 345)
Necrosis, n (%) 0 (0) 5 (4.8) 5 (3.2) 0 (0) 10 (2.9)
Number of occurrences
1 0 3/5 (60.0) 2/5 (40.0) 0 5/10 (50.0)
2 0 1/5 (20.0) 2/5 (40.0) 0 3/10 (30.0)
Unknown 0 1/5 (20.0) 1/5 (20.0) 0 2/10 (20.0)
Severity
Mild 0 3/5 (60.0) 1/5 (20.0) 0 4/10 (40.0)
Moderate 0 0 3/5 (60.0) 0 3/10 (30.0)
Severe 0 1/5 (20.0) 0 0 1/10 (10.0)
Unknown 0 1/5 (20.0) 1/5 (20.0) 0 2/10 (20.0)
Lipoatrophy, n (%) 0 (0)
a 9 (8.7) 23 (15.0)
b 1 (7.1) 33 (9.6)
Number of occurrences
1 0 3/9 (33.3) 4/23 (17.4) 0 7/33 (21.2)
2 0 2/9 (22.2) 11/23 (47.8) 1/1 (100) 14/33 (42.4)
3 0 3/9 (33.3) 3/23 (13.0) 0 6/33 (18.2)
4 0 0 1/23 (4.3) 0 1/33 (3.0)
≥5 0 1/9 (11.1) 3/23 (13.0) 0 4/33 (12.1)
Unknown 0 0 1/23 (4.3) 0 1/33 (3.0)
Severity
Mild 0 6/9 (66.7) 11/23 (47.8) 0 17/33 (51.5)
Moderate 0 2/9 (22.2) 6/23 (26.1) 1/1 (100) 9/33 (27.3)
Severe 0 1/9 (11.1) 1/23 (4.3) 0 2/33 (6.1)
Unknown 0 0 5/23 (21.7) 0 5/33 (15.2)
aP = 0.011 vs SC IFNb-1b; P < 0.0001 vs SC IFNb-1a.
bLipoatrophy status was not collected for 1 SC IFNb-1a patient (n = 153).
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Page 6 of 7therapy [6]. Selecting therapy with a lower risk for ISRs
and educating patients on strategies to minimize their
occurrence may help patients adhere to treatment, thus
improving their chances for optimal treatment of MS
over the long term. Although many factors are involved
when making treatment decisions, our study may have
implications in selecting initial therapy or, for patients
considering switching or discontinuing therapy because
of ISRs, selecting an alternative option.
Conclusions
More patients remained on IM IFNb-1a compared with
other DMTs over the 1-year study. Patients on IM
IFNb-1a had fewer skin reactions and better compliance
and were less likely to switch to other DMTs compared
with patients on other therapies. Minimizing the impact
of adverse effects is crucial in helping patients adhere to
their treatment regimens and in improving their chances
of better health over the longer term.
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